Feng Zhu

Feng Zhu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in JHEP Reports
Verified
Journal Article
Open access
CZChengfei Zhang
Chengfei Zhang
YZYangchun Zhou
Yangchun Zhou
MHMinghua Hu
Minghua Hu
YPYue Pan
Yue Pan
XCXin Chen
Xin Chen
HXHongping Xia
Hongping Xia
Procollagen lysyl hydroxylase 1 (PLOD1) is crucial in regulating collagen synthesis and cross-linking. However, its roles and underlying mechanisms in the progression of hepatocellular carcinoma (HCC) remain unclear. Herein, we aimed to investigate the underlying biological functions and mechanisms of PLOD1 in HCC. The expression levels of PLOD1 in HCC were measured by qPCR, Western blot, and immunohistochemistry. Cell proliferation, apoptosis, and stemness were examined by CCK8, flow cytometry, sphere formation, and aldehyde dehydrogenase activity assays. The subcutaneous tumorigenicity model, orthotopic tumorigenicity model, and hepatotoxin-induced HCC model were used for in vivo experiments. RNA-sequence and untargeted metabolomics analysis were performed to identify underlying mechanisms. PLOD1 is found to be highly expressed in both human (p <0.0001) and mouse HCC (p <0.01) and is associated with a poor prognosis (p = 0.047). In vitro and in vivo experiments reveal that overexpression of PLOD1 promotes the proliferation and stemness of HCC cells. Meanwhile, the depletion of PLOD1 attenuates the occurrence and growth of HCC, leading to cell cycle arrest (p <0.01) and apoptosis (p <0.001) in HCC. Mechanistically, PLOD1 positively regulates the NF-κB/IL-6/STAT3 signaling pathway and accelerates TCA cycle metabolic reprogramming. Blocking the NF-κB/IL-6/STAT3 signaling pathway and TCA cycle can effectively mitigate PLOD1-induced proliferation and stemness of HCC cells. Our study uncovers the PLOD1/NF-κB/IL-6/STAT3 axis as a therapeutic target for inhibiting the progression and stemness of HCC. The roles and underlying mechanisms of PLOD1 in the progression of HCC remain unclear. In this study, we report that PLOD1 is highly expressed in patients with HCC and promotes the proliferation and stemness of HCC cells by activating the NF-κB/IL-6/STAT3-dependent TCA cycle. Knocking down hepatic PLOD1 using adeno-associated virus results in reduced progression of HCC in mice, suggesting that PLOD1 may serve as a potential therapeutic target for HCC.

23 August 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
XCXin Chen
Xin Chen
XWXiaodong Wang
Xiaodong Wang
FZFeng Zhu
Feng Zhu
CQChao Qian
Chao Qian
FXFanggui Xu
Fanggui Xu
BSBeicheng Sun
Beicheng Sun
Background and Aim. Chronic hepatitis B virus (HBV) infection is the leading global cause of hepatocellular carcinoma (HCC). Few studies have been conducted concerning the HBV infection-related genes and their function. Methods. We compared differentially expressed genes (DGEs) in HBV-positive and -negative tumor samples and conducted a Spearman correlation study between the DGEs and HBV titers within The Cancer Genome Atlas (TCGA). Moreover, we validated the results of our in-house samples. Results. In this study, we discovered a series of genes that correlated statistically with HBV infection based on the TCGA database. These genes were related to increased inflammation and some oncogenic signaling pathways via Gene Set Enrichment Analysis (GSEA). PDZK1 is an ideal gene, which mostly relates positively to HBV infection; moreover, it is overexpressed in human HCC, especially in those HBV-infected HCCs. After analyzing the TCGA data and performing a verification study using our own samples, PDZK1 expression was investigated to be significantly associated with PI3K-Akt signaling and fatty acid metabolism. Further, single-sample GSEA analysis of tumor immune cell infiltration gene sets revealed that high PDZK1expression in HCC tissues was significantly associated with increased tumor-associated macrophages (TAMs) and regulatory T cells(Tregs). Conclusions. PDZK1 is an HBV infection-related gene, which plays oncogenic roles, possibly due to enhancing PI3K-Akt, fatty acid usage in tumor cells and TAMs, and Treg-induced immunosuppression.

2 August 2025 in Cancer Medicine
Verified
Journal Article
Open access
HYHang Yin
Hang Yin
YPYue Pan
Yue Pan
ZLZhuang Li
Zhuang Li
YLYong Liu
Yong Liu
JCJiatong Chen
Jiatong Chen
YCYu Chunzhao
Yu Chunzhao
Background: Collagen triple helix repeat containing 1 (CTHRC1) is a secreted protein involved in tissue remodeling and fibrotic processes, which also suggests emerging roles in cancer. Studies have shown that it is mainly expressed in the outer membrane fibroblasts of injured arteries and in the neointimal smooth muscle cells, where it promotes cell migration and tissue damage repair. However, the regulatory role of CTHRC1 as a tumor microenvironment factor in pancreatic cancer is not well understood. Methods: We employed multi‐omics analysis combined with cellular and animal experiments to examine the association between CTHRC1 and the LIF/STAT3 pathway in pancreatic cancer clinical specimens. Using AsPC‐1/PANC‐1 and other cell lines, we conducted proliferation, migration, invasion, and signaling pathway studies, and elucidated the regulatory mechanism of CTHRC1 through genetic interventions and STAT3 inhibitors. Results: In this study, we found that CTHRC1 is highly expressed in the cancer‐associated fibroblasts (CAFs) of pancreatic cancer and is associated with poor prognosis in patients. Functionally, we observed that CTHRC1 in CAFs promotes the proliferation, migration, and invasion of pancreatic cancer cells both in vitro and in vivo. In mechanistic studies, RNA sequencing revealed that CTHRC1 promotes the proliferation and migration of pancreatic cancer cells through the LIF‐mediated STAT3 axis. Conclusion: These findings reveal the role of CTHRC1 in CAFs in pancreatic cancer, suggesting that it is an attractive therapeutic target and tumor marker. This study uncovers the biological mechanism of CTHRC1 in CAFs in pancreatic cancer, providing new strategies for the treatment of pancreatic cancer.

30 July 2022 in Journal of Proteomics
Verified
Journal Article
Closed access
JWJing Wu
Jing Wu
HLHe Liu
He Liu
HWHaiquan Wang
Haiquan Wang
YWYuqi Wang
Yuqi Wang
QCQi Cheng
Qi Cheng
BXBin Xue
Bin Xue

31 December 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
CZChengfei Zhang
Chengfei Zhang
PXPing Xu
Ping Xu
YWYongsheng Wang
Yongsheng Wang
XCXin Chen
Xin Chen
YPYue Pan
Yue Pan
HXHongping Xia
Hongping Xia
Evading host immunity killing is a critical step for virus survival. Inhibiting viral immune escape is crucial for the treatment of viral diseases. Serine/threonine kinase 39 (STK39) was reported to play an essential role in ion homeostasis. However, its potential role and mechanism in viral infection remain unknown. In this study, we found that viral infection promoted STK39 expression. Consequently, overexpressed STK39 inhibited the phosphorylation of interferon regulatory factor 3 (IRF3) and the production of type I interferon, which led to viral replication and immune escape. Genetic ablation or pharmacological inhibition of STK39 significantly protected mice from viral infection. Mechanistically, mass spectrometry and immunoprecipitation assays identified that STK39 interacted with PPP2R1A (a scaffold subunit of protein phosphatase 2A (PP2A)) in a kinase activity-dependent manner. This interaction inhibited DDB1 and CUL4 associated factor 1 (DCAF1)-mediated PPP2R1A degradation, maintained the stabilization and phosphatase activity of PP2A, which, in turn, suppressed the phosphorylation of IRF3, decreased the production of type I interferon, and then strengthened viral replication. Thus, our study provides a novel theoretical basis for viral immune escape, and STK39 may be a potential therapeutic target for viral infectious diseases.

20 August 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
ZLZhuang Li
Zhuang Li
YLYong Liu
Yong Liu
HYHang Yin
Hang Yin
JCJiatong Chen
Jiatong Chen
FZFeng Zhu
Feng Zhu
Horner syndrome is a rare complication following thyroid surgery, typically presenting with ptosis, miosis, and ocular congestion. We report the case of a 30-year-old female diagnosed with papillary thyroid carcinoma who underwent left thyroid lobectomy, isthmectomy, and comprehensive left cervical lymph node dissection. On the first postoperative day, the patient developed left-sided ptosis, a constricted pupil, blurred vision, and conjunctival congestion, leading to a clinical diagnosis of Horner syndrome. Initial treatment with oral neurotrophic agents provided limited improvement, with persistent ocular symptoms. Four months postoperatively, the introduction of topical naphazoline eye drops resulted in marked improvement. Ptosis diminished, the palpebral fissure returned to normal, pupil sizes equalized, and conjunctival congestion resolved, with effects lasting approximately 2 h after each application. This case report summarizes the mechanisms of injury leading to Horner syndrome after thyroid surgery, highlighting the importance of understanding the anatomical relationship between the thyroid gland and the cervical sympathetic nerve trunk during thyroidectomy to minimize the risk of Horner syndrome. This case highlights the potential role of topical α 1 -adrenergic agonists in managing postoperative Horner syndrome and underscores the need for intraoperative nerve protection strategies.